Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002037 · ClinicalTrials.gov registry record · Phase 4
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT04002037: Clinical Trial Phase 4 study, sponsored by University of Missouri-Columbia.
NCT04002037 is a Phase 4 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 95 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04002037, a Phase 4 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
Trigger finger is a common cause of hand pain and dysfunction. Its due to chronic inflammation of the flexor tendon that leads to a pulley system mismatch. Historically it has been managed either conservatively with corticosteroid injections or through a surgical release of the A1 pulley. Several corticosteroids have been used for injection- dexamethasone, methylprednisolone, triamcinolone, betamethasone, paramethasone, etc. The purpose of out study is to determine if a 0.5 cc injection of Triamcinolone 40 mg/mL will be the most effective steroid injection for the non-surgical treatment. Approximately 200 subjects will be enrolled and randomized to one of three treatment arms: Triamcinolone 40mg/mL, Triamcinolone 10mg/mL and Soluble dexamethasone 4mg/mL. Treatment success will be defined as lack of conversion to surgical treatment, or no desire to proceed with surgery during study period (3 months).
Primary Outcome
The patient will be asked to complete a questionnaire with questions related to their hand. Their answers will be scored on a scale of 0-100 with 0 being no disability and 100 being the highest level of disability.
Interventions
- DRUG Triamcinolone Acetonide 40mg/mL
- DRUG Triamcinolone Acetonide 10mg/mL
- DRUG Dexamethasone 4 mg/ml
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2023-01-01 |
| Phase | Phase 4 |
Why NCT04002037 stopped before completion
NCT04002037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which Triamcinolone Acetonide 40mg/mL is the first listed.
NCT04002037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04002037 about?
NCT04002037 is a clinical study titled "Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis". Trigger finger is a common cause of hand pain and dysfunction. Its due to chronic inflammation of the flexor tendon that leads to a pulley system mismatch. Historically it has been managed either conservatively with corticosteroid injections or through a surgical release of the A1 pulley. Several co...
What is the current status of trial NCT04002037?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2019-06-25. Estimated completion is 2023-01-01.
What interventions are being tested in trial NCT04002037?
The interventions under investigation include: Triamcinolone Acetonide 40mg/mL (DRUG), Triamcinolone Acetonide 10mg/mL (DRUG), Dexamethasone 4 mg/ml (DRUG).
Who is sponsoring clinical trial NCT04002037?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04002037's enrollment target sits among peer trials
95 869th of 2000 higher than 1,130 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI